A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.
Cristina Martin-Lorente,David S.P. Tan,Neesha C. Dhani,Marcus O. Butler,Helen Mackay,Michelle K. Wilson,Stephanie Lheureux,Hal W. Hirte,Stephen Welch,Johanne I Weberpals,Ghatage Prafullg,Katia Tonkin,Lisa Wang,Anna Haley,Stephanie Capobianco,Amit M. Oza +15 more
TL;DR: In a Phase II study in platinum-resistant EOC, 58% of the patients treated with single agent ENMD-2076 showed partial response or stable disease, the PFS at 6 month was 22% with a median time to progression of 3.6 months.
Journal ArticleDOI
A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer
Willem M. Smit,Jozef Sufliarsky,Theresa L. Werner,Don S. Dizon,Maria Wagnerova,H. Hirte,Nick M. Spirtos,Amit M. Oza,Luc Dirix,Mona El-Hashimy,Suddhasatta Acharyya,Eugene Y. Tan,Dirk Weber,Jan H.M. Schellens,Jan H.M. Schellens +14 more
TL;DR: Patupilone was well tolerated and demonstrated an encouraging disease control rate in patients with platinum-resistant or -refractory ovarian, primary fallopian tube, or primary peritoneal cancer; this is a challenging population with a poor prognosis.
Journal ArticleDOI
Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.
Neesha C. Dhani,Hal W. Hirte,Marcus O. Butler,Stephanie Lheureux,Julie Burnier,Michelle K. Wilson,Angela Jain,Mihaela C. Cristea,Stephen Welch,Waldo Jimenez,Daniela Matei,Katia Tonkin,Erica M. Stringer,Carolyn Johnston,Judy Quintos,Christine Tran,Katherine Karakasis,Lisa Wang,John J. Wright,Amit M. Oza +19 more
TL;DR: PHL86/NCI#9322/NCT01935934 is a multi-centre, phase II trial of cabozantinib in patients with EC recurring within a year of adjuvant chemotherapy, or with progression after 1 line of chemotherapy for metastatic disease.
Journal ArticleDOI
Dr. Swart and colleagues reply
Journal ArticleDOI
A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).
Susana Banerjee,Amit M. Oza,Michael J. Birrer,Erika Hamilton,Jurjees Hasan,Alexandra Leary,Kathleen N. Moore,Beata Mackowiak-Matejczyk,Joanna Pikiel,Isabelle Ray-Coquard,Peter Trask,Kedan Lin,Anjali Vaze,YounJeong Choi,Jim Marsters,Daniel J. Maslyar,Vanessa Lemahieu,Yulei Wang,Eric W. Humke,Joyce F. Liu +19 more
TL;DR: This data indicates that Lifa, a humanized anti-NaPi2b monoclonal antibody conjugated to the anti-mitotic agent MMA, acts as a “spatially aggregating force” to knock down NaPi2B in OC.